Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a268b3950ecb70f3

Jump to content

// Workers AI · dad joke modeWhy did StemCells, Inc. go to therapy? It had a lot of cell-ebration issues.

From Wikipedia, the free encyclopedia
StemCells, Inc.
TypePublic
IndustryBiotechnology
Founded1 January 1992 Edit this on Wikidata
Headquarters,
United States Edit this on Wikidata
Key people
Ian Massey (CEO)
Irving L. Weissman, M.D. (Founder)
Websitewww.stemcellsinc.com

StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.[1][2]

They are being studied in early stage trials.[3][4]

In March 2020, Microbot Medical Inc. announced the appointment of Eyal Morag, M.D. to Chief Medical Officer.[5]

References

[edit]
  1. Falco, Miriam. (Sept. 7, 2012). "A tiny step forward for spinal cord injuries."
  2. Le Roux, Mariette. (March 5, 2014). "Science sees future beyond Paralympics."
  3. http://www.clinicaltrials.gov/ct2/show/NCT02163876
  4. "StemCells Inc says spinal injury therapy shows promise". Reuters. 2015-11-18. Retrieved 2015-12-23.
  5. "Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer". BioSpace. Retrieved 2020-03-03.
[edit]